Delivery Order SPE2DB24D2106-SPE2DB25FAVVJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, on August 4, 2025, for the supply of Lisdexamfetamine 30 mg capsules in quantities of 100. This firm fixed-price delivery order, valued at $1,388.47, is set to be completed by August 5, 2025, with performance taking place in Conshohocken, Pennsylvania. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on equal...
- The Defense Logistics Agency awarded a delivery order valued at $2,027.13 to DMS Pharmaceutical Group Inc. for Lisdexamfetamine 70 mg capsules (90-count) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents performance at DMS Pharmaceutical Group's facility in Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,000.98 contract is for the delivery of 4,567,329,296 lisdexamfetamine 20 mg capsules, and has an ultimate completion date of February 21, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,281.36 firm fixed-price contract is for the delivery of 100 units of the prescription drug lisdexamfetamine 70 mg capsules. The contract has a completion date of July 9, 2025 and does not have a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $2,135.88 award is for the delivery of 100 units of 30mg lisdexamfetamine capsules. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the agency to issue delivery orders for a wide range of pharmaceutical products,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,070.16, is for the delivery of 4,567,197,276 units of the prescription drug Lisdexamfetamine 20 mg capsules. The award has a completion date of February 7, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite...
- This is a federal contract award by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a delivery order valued at $1,176.64 for the supply of 4567764395 Lisdexamfetamine 50 mg capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of April 2, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,367.72, is for the delivery of 4,567,997,741 units of the prescription drug lisdexamfetamine 20 mg capsules. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 held by DMS Pharmaceutical Group with the DLA, which enables the agency to issue delivery...
- This is a $1,272.52 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 100 units of 60 mg lisdexamfetamine capsules. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Lisdexamfetamine 40 mg capsules in 100-count packages, with a ceiling value of $1,285.85 and a completion date of June 16, 2025. The contract is not set aside for any specific socioeconomic program. DMS Pharmaceutical Group Inc. has a...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAVVJDelivery Order
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for Lisdexamfetamine 30 mg capsules (90-count units) with a ceiling value of $1,191.06. This firm fixed-price delivery order represents a specific pharmaceutical supply requirement under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, valued at $499,999,999 and valid through November 2026. The place of performance is Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this delivery order without a set-aside designation, leveraging its competitive position in federal procurement markets. This delivery order supports the Department of Defense's pharmaceutical supply chain through DMS Pharmaceutical Group's established role as a critical supplier of prescription medications and medical consumables to military health facilities. The company's SPE2DB program contract with DLA enables the issuance of firm fixed-price delivery orders across a comprehensive portfolio of pharmaceutical products, including branded and generic prescription drugs, biologics, and specialty medications. The ultimate completion date for this delivery is July 25, 2025, reflecting the time-sensitive nature of pharmaceutical supply to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/24/25 |